Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS
Home/The Filing Wire/Indivior Pharmaceuticals, Inc./ EFFECT

Notice of Effectiveness · EFFECT

Indivior Pharmaceuticals, Inc.

INDVNASDAQEQUITYCurrent

Notice of Effectiveness

Filed Sep 11, 2026Accepted Sep 14, 2026, 12:15 AM EDTCIK 1625297Accession 9999999995-26-002953
View company →Permanent SEC source ↗
Share

Company context

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine, developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together - with science, people living with OUD, public health champions, and communities - we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

Current securities

INDVNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding Indivior Pharmaceuticals, Inc.Sep 30, 2026
  2. 425 filingSep 17, 2026
  3. Regulation FD Disclosure · Other EventsSep 17, 2026
  4. Termination of a Material Definitive AgreementSep 15, 2026
  5. 424B3 filingSep 11, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.